0.4430SEK-3.70%Mkt Cap: 26.22M SEKP/E: —Last update: 2026-06-01
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleaso…
Industry Peers
Diagnostics & Research183.26BUSDP/E 27.1
127.46BUSDP/E 35.0
45.09BUSDP/E 42.1
38.48BUSDP/E 27.4
37.00BUSDP/E 47.9
34.66BCHFP/E 38.1
31.51BUSD—
31.45BUSDP/E 23.4
Indicators:|
Key Statistics
Company
Market Cap26.22M SEK
Enterprise Value18.16M SEK
Revenue (TTM)594.00K SEK
Gross Profit594.00K SEK
Net Income (TTM)-44.50M SEK
Revenue/Share0.0180 SEK
Last Price0.4430 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees6
CountrySE
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.60
PEG—
EV/EBITDA-0.49
EV/Revenue30.57
P/S45.84
P/B1.03
EPS (TTM)-1.32
EPS (Forward)-0.10
52W Range
0.28005% of range3.560
52W High3.560 SEK
52W Low0.2800 SEK
Profitability
Gross Margin100.00%
Oper. Margin-5423.28%
EBITDA Margin0.00%
Profit Margin-7492.09%
ROE-167.75%
ROA-87.50%
Growth
Revenue Growth-26.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.80M SEK
CapEx (TTM)13.44M SEK
FCF Margin-3344.72%
FCF Yield-75.77%
Net Debt-9.07M SEK
Net Debt/EBITDA0.25
Balance Sheet
Debt/Equity—
Current Ratio0.44
Quick Ratio0.43
Book Value/Sh0.4480 SEK
Cash/Share0.1530 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:1000
Split DateOct 31, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.59.19M
Float56.05M
Insiders28.84%
Institutions0.00%
Technical
SMA 500.7510 (-41.0%)
SMA 2000.7911 (-44.0%)
Beta1.52
S&P 52W Chg27.70%
Avg Vol (30d)232.19K
Avg Vol (10d)326.60K
Technical Indicators
RSI (14)35.0
MACD-0.1011
MACD Signal-0.0930
MACD Hist.-0.0081
BB Upper0.8921 SEK
BB Middle0.6007 SEK
BB Lower0.3093 SEK
BB Width97.02%
ATR (14)0.1094 SEK
Vol Ratio (20d)0.35x